Center-Authored Papers

Filters: Author is Prince, H Miles  [Clear All Filters]
C
Coiffier B, Pro B, Prince MH, Foss F, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Pinter-Brown L et al..  2014.  Romidepsin for the treatment of relapsed/refractory peripheral T-cell lymphoma: pivotal study update demonstrates durable responses.. Journal of hematology & oncology. 7:11. Abstract
P
Prince MH, Kim YH, Horwitz SM, Dummer R, Scarisbrick J, Quaglino P, Zinzani PL, Wolter P, Sanches JA, Ortiz-Romero PL et al..  2017.  Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial.. Lancet (London, England). Abstract
Pro B, Horwitz SM, Prince MH, Foss FM, Sokol L, Greenwood M, Caballero D, Morschhauser F, Wilhelm M, Padmanabhan Iyer S et al..  2016.  Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T-cell lymphoma.. Hematological oncology.